A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
Qilu Pharmaceutical Co., Ltd.
City of Hope Medical Center
Merck Sharp & Dohme LLC
Incyte Corporation
Eli Lilly and Company
AstraZeneca